Comprehensive medication guide to Atzumi including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Most insurance plans require prior authorization for Atzumi. When covered, Atzumi is typically placed on specialty or Tier 3–4 formulary, resulting in copays of $50–$200+ per fill depending on the plan. Manufacturer copay cards may reduce costs for commercially insured patients. Medicare Part D coverage varies by plan; check your formulary.
Estimated Cash Pricing
Atzumi is a brand-name-only product with no generic equivalent, approved April 2025. Estimated cash price is $900–$1,200+ for a carton of 8 single-dose nasal devices. No significant discount card pricing established yet for this newly-launched drug; contact Satsuma Pharmaceuticals at satsumarx.com or 1-888-273-2480 for current savings options.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Atzumi is a prescription migraine medication containing dihydroergotamine mesylate (DHE), an ergot alkaloid with over 70 years of use in migraine treatment. It was FDA-approved on April 30, 2025, and is manufactured by Satsuma Pharmaceuticals, Inc. (Durham, NC). Atzumi is the first and only DHE nasal powder — a drug-device combination that delivers DHE in dry powder form directly to the nasal mucosa for rapid systemic absorption.
Atzumi is indicated for the acute treatment of migraine with or without aura in adults. It is an on-demand treatment taken when a migraine starts — it does not prevent migraines. Each single-use device contains 5.2 mg of dihydroergotamine (equivalent to 6.0 mg DHE mesylate) and is administered by squeezing the device's air pump three times into one nostril while inhaling. The carton contains 8 individual devices.
Atzumi uses the proprietary SMART (Simple MucoAdhesive Release Technology) platform, which enables rapid and consistent drug absorption. In Phase 1 pharmacokinetic studies, Atzumi achieved effective DHE plasma concentrations within approximately 10 minutes, significantly faster than liquid DHE nasal spray formulations.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Atzumi contains dihydroergotamine (DHE), which works through multiple mechanisms to stop a migraine attack. DHE is a serotonin receptor agonist — it activates 5-HT1B, 5-HT1D, and 5-HT1F receptors on intracranial blood vessels and trigeminal nerve endings. This causes vasoconstriction (narrowing) of abnormally dilated cranial blood vessels and suppresses the release of inflammatory neuropeptides (including CGRP) that drive migraine pain.
Unlike triptans, DHE also acts on alpha-adrenergic receptors and dopaminergic receptors. This broader pharmacological profile makes DHE effective in patients who don't respond to triptans, effective even when taken late in a migraine attack (after central sensitization has developed), and associated with lower migraine recurrence rates than most triptans.
DHE also inhibits CGRP-mediated cranial vasodilation — addressing the same key pathway targeted by newer gepant drugs (ubrogepant, rimegepant) but through a different mechanism. The drug is absorbed through the nasal mucosa and enters the systemic circulation, bypassing the gastrointestinal tract — an important advantage during migraines that involve nausea and gastroparesis.
5.2 mg (6.0 mg DHE mesylate) — nasal powder
Single-dose device; one device per dose; maximum 2 doses per 24 hours
Atzumi was FDA-approved on April 30, 2025, and like most newly-launched specialty medications, finding it at a standard retail pharmacy can be challenging in 2026. Most retail pharmacies do not yet routinely stock Atzumi — its high cash price ($900–$1,200+ per carton) makes pharmacies hesitant to hold inventory without confirmed demand. Insurance prior authorization is required by most major pharmacy benefit managers, adding additional delay between prescription and fill.
Atzumi is not listed on the FDA's official drug shortage database — the access challenges are structural (new drug distribution, insurance PA requirements) rather than a manufacturing issue. Availability is expected to improve as prescriptions grow and distribution matures throughout 2026. To find pharmacies near you that currently have Atzumi in stock, use medfinder — medfinder calls pharmacies on your behalf and texts you which ones can fill your prescription.
Atzumi is not a controlled substance, so any licensed prescriber with a standard DEA registration can prescribe it. No special DEA authorization or additional licensing is required beyond the ability to prescribe standard prescription medications. However, prescribers should be familiar with Atzumi's Boxed Warning, cardiovascular evaluation requirements, and contraindications before initiating therapy.
The following providers commonly prescribe Atzumi and other DHE medications:
Neurologists: Most familiar with DHE class medications; ideal prescriber for complex or refractory migraine
Board-certified headache specialists: Sub-specialty trained in migraine management; most up-to-date on new formulations like Atzumi
Primary care physicians (family medicine, internal medicine): Can prescribe Atzumi; may be less familiar with new DHE formulations
Nurse practitioners and physician assistants: Can prescribe in most states; NPs/PAs in neurology practices often prescribe DHE class medications
Telehealth prescribing of Atzumi is possible since it is not a controlled substance. However, the prescribing information recommends a cardiovascular evaluation before initiation, and for patients with cardiovascular risk factors, the first dose should ideally be administered in a clinical setting. Telehealth providers should assess whether they can adequately fulfill these requirements before prescribing remotely.
No. Atzumi (dihydroergotamine nasal powder) is not a DEA-scheduled controlled substance. It does not appear on any DEA drug schedule (Schedules I through V). This means Atzumi can be prescribed by any licensed prescriber — physicians, nurse practitioners, and physician assistants with prescribing authority — without any special DEA registration beyond a standard DEA number. Prescriptions can also be called in, faxed, or transmitted electronically without the additional restrictions that apply to controlled substances.
While Atzumi is not controlled, it does have a Boxed Warning and other significant safety considerations. A cardiovascular evaluation is recommended before initiation, and prescribers should assess patients for cardiovascular risk factors before prescribing. The absence of controlled substance scheduling means there are no refill limitations based on DEA regulations — refill policies are determined by prescriber judgment and pharmacy practice standards.
The following side effects occurred in more than 1% of patients in Atzumi clinical trials:
Rhinitis (nasal irritation or runny nose)
Nausea
Altered sense of taste
Application site reactions (nasal burning, irritation)
Dizziness
Vomiting
Somnolence (drowsiness)
Pharyngitis (sore throat)
Diarrhea
Serious side effects (seek emergency care):
Peripheral ischemia (cerebral or extremity) — BOXED WARNING when used with CYP3A4 inhibitors
Myocardial ischemia or infarction (heart attack)
Cerebrovascular events (stroke, hemorrhage)
Bronchospasm (in patients with asthma or COPD)
Significant blood pressure elevation
Medication overuse headache (with frequent use)
Know what you need? Skip the search.
Trudhesa (dihydroergotamine mesylate nasal spray)
Same drug class (DHE), liquid precision nasal spray (Impel NeuroPharma, 2021 approval); established formulary coverage; similar clinical profile
Generic dihydroergotamine nasal spray (Migranal generic)
Same active ingredient, liquid formulation; lower cost (~$100-200/dose); widely available; less consistent absorption than Atzumi SMART technology
Sumatriptan (Imitrex)
Most prescribed triptan; first-line for moderate-severe migraine; available in oral, nasal, and subcutaneous forms; generic widely available
Ubrelvy (ubrogepant)
Oral CGRP receptor antagonist; no cardiovascular contraindications; effective during aura phase; good option for patients who cannot use DHE
Nurtec ODT (rimegepant)
Oral disintegrating CGRP antagonist; dual-use for acute treatment and prevention; no vasoconstriction
Prefer Atzumi? We can find it.
Strong CYP3A4 inhibitors (clarithromycin, erythromycin, HIV protease inhibitors)
majorCONTRAINDICATED — Boxed Warning. Elevates DHE serum levels causing vasospasm, peripheral ischemia, cerebral ischemia.
Triptans (sumatriptan, rizatriptan, eletriptan, etc.)
majorDo not use within 24 hours — additive coronary artery vasospasm risk.
Other ergotamine products
majorDo not use within 24 hours — excessive vasoconstriction risk.
Moderate CYP3A4 inhibitors (fluconazole, verapamil, diltiazem)
moderateUse with caution — may increase DHE blood levels.
Beta-blockers (propranolol, metoprolol)
moderateUse with caution — may potentiate peripheral vasoconstriction.
SSRIs/SNRIs/MAOIs
moderateCaution — theoretical serotonin syndrome risk; nonselective MAOIs contraindicated.
Grapefruit juice
moderateAvoid — natural CYP3A4 inhibitor that can increase DHE levels.
Atzumi (dihydroergotamine nasal powder) represents a meaningful advance in the management of acute migraine. By delivering DHE — a clinically proven migraine treatment with over 70 years of evidence — through a more convenient, faster-absorbing dry powder platform, Atzumi brings renewed utility to a drug class with unique advantages for triptan non-responders, late-presenting attacks, and patients with frequent migraine recurrence.
The main challenges in 2026 are the practical access barriers typical of a newly-launched specialty drug: limited retail pharmacy stocking, insurance prior authorization requirements, and a high cash price with no generic alternative. These barriers are expected to ease as the drug's distribution network matures and formulary coverage standardizes throughout the year.
If you have been prescribed Atzumi and are having trouble finding it at a pharmacy, medfinder can help. medfinder calls pharmacies near you to check which ones have Atzumi in stock, then texts you the results — saving you hours of phone calls and making it faster to get the medication you've been prescribed.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini